Visão geral da empresa
A biotechnology enterprise, Prime Medicine, Inc., focuses on delivering genetic medicines to address a spectrum of diseases through the deployment of gene editing technology within the United States. This operational model places the company firmly within the Healthcare sector, specifically targeting the specialized Biotechnology industry where innovation drives product development. The firm currently employs 146 individuals and holds a market capitalization of $639.15M while reporting trailing twelve-month revenue of $4.63M. These valuation and revenue figures indicate that the company operates as a mid-sized entity with significant potential for expansion, yet its revenue scale remains modest relative to its market cap, suggesting a high valuation multiple driven by future clinical potential rather than current cash flow generation.
Saúde financeira
Prime Medicine, Inc. reported a net income of $-201,142,000 and EBITDA of $-201,028,992 against total revenue of $4.63M during the trailing twelve months. The substantial gap between the minimal revenue and the massive net loss reveals a cost structure heavily weighted toward research and development expenses, clinical trial costs, and operational overheads typical of early-stage biotechnology firms. The company generated free cash flow of $-85,365,752, which indicates that its cash burn rate is currently high, necessitating external capital raises to sustain operations and fund ongoing clinical programs. Regarding profitability metrics, the gross margin stands at 0.0%, the operating margin is -5800.5%, and the profit margin is 0.0%, collectively indicating that the company is not yet commercially profitable and that its current financial model relies entirely on non-operating assets to cover losses. On the balance sheet, the company holds cash of $177.68M against total debt of $116.43M, resulting in a debt-to-equity ratio of 96.33; this configuration suggests a leveraged position where debt is nearly equal to equity, though the substantial cash reserve provides a buffer against short-term obligations. The current ratio of 4.84 indicates strong short-term liquidity, as the company possesses more than four times the current assets required to settle its current liabilities without needing to liquidate long-term assets or incur new debt. Furthermore, the return on equity is -146.8% and the return on assets is -40.7%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate negative returns due to the company's heavy investment phase and lack of commercial product sales.
Avaliação de valorização
The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -4.36, a discrepancy that implies the market is pricing the stock based on anticipated future profitability rather than historical performance, reflecting high uncertainty regarding the earnings trajectory. The price-to-book ratio stands at 5.18, indicating that the market values the company at more than five times its net asset value, suggesting a significant premium assigned to the company's intangible assets, such as intellectual property and pipeline potential. Alternative valuation metrics like the price-to-sales ratio of 137.99 and the EV/EBITDA of -2.81 suggest that the stock is priced extremely high relative to its revenue generation and earnings power, a common characteristic for biotechnology firms awaiting clinical data. The 52-week high was $6.94 and the 52-week low was $1.11; without a specific current share price provided in the available facts, the precise percentage deviation from this range cannot be calculated, but the wide trading range demonstrates significant price volatility over the last year. The beta of 2.67 indicates that the stock is highly volatile, moving with roughly 2.67 times the magnitude of the broader market, which exposes investors to substantial price swings during periods of market turbulence.
Growth & Income
Prime Medicine, Inc. experienced a revenue growth of -61.6% year-over year, while earnings growth is listed as N/A due to losses; the negative revenue growth suggests a contraction in sales or a transition period following a major clinical event or commercial launch. Since the company is not a dividend payer, indicated by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute profits to shareholders, instead choosing to reinvest any available earnings into research, development, and clinical trials to accelerate pipeline progression. The overall growth and income profile is characterized by significant revenue contraction and a complete reliance on external funding rather than organic earnings or dividend income to support shareholder returns and operational continuity.